Next-Generation Immunotherapies to Improve Anticancer Immunity.
Next-Generation Immunotherapies to Improve Anticancer Immunity.
复制标题
DOI：
10.3389/fphar.2020.566401
复制
发表时间：
2020
影响因子：
5.6
通讯作者：
Haymaker C
中科院分区：
文献类型：
--
作者：
Shi Y;Tomczak K;Li J;Ochieng JK;Lee Y;Haymaker C
检查点抑制剂是广泛用于晚期癌症的免疫疗法。尽管如此，检查点抑制剂的反应率相对较低，在有限的癌症范围内起作用，并且具有一些不可消除的副作用。检查点抑制剂旨在重振肿瘤微环境（TME）中耗尽或抑制的T细胞。然而，TME含有各种其他免疫细胞亚群，它们相互作用以决定细胞毒性T细胞的命运。细胞毒性T细胞的活化由树突状细胞的抗原交叉呈递启动。树突状细胞还可以释放趋化因子和细胞因子来募集和培养T细胞。B细胞是另一种类型的抗原呈递细胞，也可以培养T细胞并产生肿瘤特异性抗体。中性粒细胞，TME中的粒细胞亚群，阻碍T细胞的增殖和活化。TME还由细胞毒性先天性自然杀伤细胞组成，其有效地杀死肿瘤细胞。自然杀伤细胞可以根除主要组织相容性复合物I阴性肿瘤细胞，其逃避细胞毒性T细胞介导的破坏。全面了解TME的免疫机制，如本文所述，将导致进一步开发更强大的治疗策略。我们还回顾了使用靶向这些免疫细胞的药物治疗患者的临床结果，以确定改善策略和可能的免疫治疗组合。
Checkpoint inhibitors are widely used immunotherapies for advanced cancer. Nonetheless, checkpoint inhibitors have a relatively low response rate, work in a limited range of cancers, and have some unignorable side effects. Checkpoint inhibitors aim to reinvigorate exhausted or suppressed T cells in the tumor microenvironment (TME). However, the TME contains various other immune cell subsets that interact to determine the fate of cytotoxic T cells. Activation of cytotoxic T cells is initiated by antigen cross-presentation of dendritic cells. Dendritic cells could also release chemokines and cytokines to recruit and foster T cells. B cells, another type of antigen-presenting cell, also foster T cells and can produce tumor-specific antibodies. Neutrophils, a granulocyte cell subset in the TME, impede the proliferation and activation of T cells. The TME also consists of cytotoxic innate natural killer cells, which kill tumor cells efficiently. Natural killer cells can eradicate major histocompatibility complex I-negative tumor cells, which escape cytotoxic T cell–mediated destruction. A thorough understanding of the immune mechanism of the TME, as reviewed here, will lead to further development of more powerful therapeutic strategies. We have also reviewed the clinical outcomes of patients treated with drugs targeting these immune cells to identify strategies for improvement and possible immunotherapy combinations.
登录
查看更多内容
倒退时间：靶向肿瘤浸润髓样细胞以恢复癌症的进展。
影响因子：
7.3
作者：
Awad RM;De Vlaeminck Y;Maebe J;Goyvaerts C;Breckpot K
通讯作者：
Breckpot K
影响因子：
7.2
作者：
Boudewijns S;Koornstra RH;Westdorp H;Schreibelt G;van den Eertwegh AJ;Geukes Foppen MH;Haanen JB;de Vries IJ;Figdor CG;Bol KF;Gerritsen WR
通讯作者：
Gerritsen WR
影响因子：
8
作者：
Antonios, Joseph P.;Soto, Horacio;Prins, Robert M.
通讯作者：
Prins, Robert M.
影响因子：
7.4
作者：
Beano, Alessandra;Signorino, Elena;Matera, Lina
通讯作者：
Matera, Lina
DOI：
10.1038/mto.2016.11
发表时间：
2016
期刊：
Molecular therapy oncolytics
影响因子：
--
作者：
通讯作者：
--